NeoPharm price target raised by Merrill

NeoPharm Inc. was maintained by Merrill Lynch analyst David Munno at a buy rating and the price target was raised to $18 per share from $15 on a view of bettering pricing for its brain cancer drug IL 13-PE38. NeoPharm shares Monday were up $0.33, or 2.84%, at $11.95 on volume of 171,540 shares versus the three-month running average of 141,082 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.